The granting of a European patent for a novel treatment method for Alzheimer's disease is a significant milestone for Cyclo Therapeutics. It not only enhances the company's intellectual property portfolio but also increases its attractiveness to investors and partners. This development could lead to increased investor confidence and potentially higher stock prices in the short term, as it represents progress towards commercialization and revenue generation in a major market.